CureVac NV banner

Wall Street
Price Targets

CVAC Price Targets Summary
CureVac NV

There are no price targets for CVAC.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
CureVac NV Competitors:
Price Targets
PTGX
Protagonist Therapeutics Inc
7% Upside
RCKT
Rocket Pharmaceuticals Inc
67% Upside
ELAN
Elanco Animal Health Inc
20% Upside

Revenue
Forecast

98% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat
98% / Year
Past Growth
-22% / Year
Estimated Growth
Estimates Accuracy
3%
Average Beat

For the last 5 years the compound annual growth rate for CureVac NV's revenue is 98%. The projected CAGR for the next 4 years is -22%.

Operating Income
Forecast

N/A
Past Growth
-27% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss
N/A
Past Growth
-27% / Year
Estimated Growth
Estimates Accuracy
-9%
Average Miss

The compound annual growth rate of CureVac NV's operating income for the next 4 years is -27%.

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is CVAC's stock price target?
Not Available

CVAC doesn't have any price targets made by Wall Street professionals.

What is CureVac NV's Revenue forecast?
Projected CAGR
-22%

For the last 5 years the compound annual growth rate for CureVac NV's revenue is 98%. The projected CAGR for the next 4 years is -22%.

What is CureVac NV's Operating Income forecast?
Projected CAGR
-27%

The compound annual growth rate of CureVac NV's operating income for the next 4 years is -27%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett